Tauopathies, characterized by the presence of abnormally phosphorylated tau aggregates, are implicated in more than 20 types of age‐related neurodegenerative diseases, including frontotemporal dementia (FTDP‐17), Alzheimer's disease (AD), progressive supranuclear palsy (PSP), and so on [1]. The gene discussed is MAPT; the disease is early-onset autosomal dominant Alzheimer disease.